Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSKB Bio
Stock Code06990
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司是一家創新的生物醫藥公司,致力于創新藥物的研發、制造及商業化,以解決中國乃至全球的醫療需求。
Listing Date2023-07-11
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國四川省成都市溫江區成都海峽兩岸科技產業開發園新華大道666號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttp://kelun-biotech.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 60.60 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share38.7%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 136,028,820

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 6,060
2 lots 200 HK$ 12,120
3 lots 300 HK$ 18,180
4 lots 400 HK$ 24,240
5 lots 500 HK$ 30,300
6 lots 600 HK$ 36,360
7 lots 700 HK$ 42,420
8 lots 800 HK$ 48,480
9 lots 900 HK$ 54,540
10 lots 1,000 HK$ 60,600
15 lots 1,500 HK$ 90,900
20 lots 2,000 HK$ 121,200
25 lots 2,500 HK$ 151,500
30 lots 3,000 HK$ 181,800
35 lots 3,500 HK$ 212,100
40 lots 4,000 HK$ 242,400
45 lots 4,500 HK$ 272,700
50 lots 5,000 HK$ 303,000
60 lots 6,000 HK$ 363,600
70 lots 7,000 HK$ 424,200
80 lots 8,000 HK$ 484,800
100 lots 10,000 HK$ 606,000
150 lots 15,000 HK$ 909,000
200 lots 20,000 HK$ 1,212,000
250 lots 25,000 HK$ 1,515,000
300 lots 30,000 HK$ 1,818,000
350 lots 35,000 HK$ 2,121,000
400 lots 40,000 HK$ 2,424,000
450 lots 45,000 HK$ 2,727,000
500 lots 50,000 HK$ 3,030,000
600 lots 60,000 HK$ 3,636,000
700 lots 70,000 HK$ 4,242,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,000 lots 100,000 HK$ 6,060,000
2,000 lots 200,000 HK$ 12,120,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap ---
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 62.5
First Day OpenHK$ 60.6
First Day Change3.14%
First Day Volume2002300.0
First Day Turnover124404000.0
Use of Proceeds
1、約45.0%或566.5百萬港元將用于研發并商業化核心產品SKB264及A166; 2、約30.0%或377.7百萬港元將用于其他主要產品的研發及商業化; 3、約12.0%或151.1百萬港元將用于為持續開發技術平臺、推進其他現有管線資產以及探索并開發新候選藥物提供資金; 4、約8.0%或100.7百萬港元將用于擴充產能及質量控制系統,以支持后期資產的預期商業化; 5、約5.0%或62.9百萬港元將用于營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 Citigroup Global Markets Asia Limited CE AAA137
Joint Bookrunners (5)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 交银国际证券有限公司 CE APJ121
Joint Lead Managers (5)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 交银国际证券有限公司 CE APJ121

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Laurion Capital Master Fund, Ltd. 56,939,760 HKD — 4.20% — 6 months 2024-01-11
2 RTW Funds 117,224,640 HKD — 8.60% — 6 months 2024-01-11
3 TruMed 56,939,760 HKD — 4.20% — 6 months 2024-01-11
4 汇添富基金管理股份有限公司 65,490,420 HKD — 4.80% — 6 months 2024-01-11
5 科伦国际发展有限公司 229,231,620 HKD — 16.90% — 6 months 2024-01-11

Directors & Management

PositionChinese nameEnglish Name
Chairman劉革新—
Company Secretary周澤劍;鐘明輝—
No director data available.

Major Shareholders

Major Shareholders & Holdings四川科倫藥業股份有限公司(55.13%);雇員激勵平臺(13.90%);默沙東(6.23%);Wealthy Linkage(3.37%);先進制造產業投資基金(3.31%)
About this page

This page shows SKB Bio (06990) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect